Prostate cancer affects 1 in 8 men, but current PSA screening methods face significant challenges leading to overdiagnosis and overtreatment. Jason Hafron of Michigan Institute of Urology discusses the limitations of PSA testing, highlighting the need for refined diagnostics such as IsoPSA and improved guidelines based on age and risk factors. Innovative approaches combining biomarkers and MRI could enhance decision-making for biopsies. As prostate cancer diagnostics evolve, a personalized risk assessment model integrating various data points is essential for effective screening.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.